Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 29;22(1):33-44.
doi: 10.9758/cpn.23.1098. Epub 2023 Aug 28.

Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment

Gerard Anmella  1   2   3   4   5 , Alcy Meehan  6 , Melanie Ashton  6 , Mohammadreza Mohebbi  6   7 , Giovanna Fico  1   2   3   4   5 , Chee H Ng  8 , Michael Maes  6   9 , Lesley Berk  6 , Michele De Prisco  1   2   3   4   5 , Ajeet B Singh  6 , Gin S Malhi  10   11   12 , Michael Berk  6   13   14   15 , Seetal Dodd  6   13   14 , Diego Hidalgo-Mazzei  1   2   3   4   5 , Iria Grande  1   2   3   4   5 , Isabella Pacchiarotti  1   2   3   4   5 , Andrea Murru  1   2   3   4   5 , Eduard Vieta  1   2   3   4   5 , Olivia M Dean  6   15
Affiliations

Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment

Gerard Anmella et al. Clin Psychopharmacol Neurosci. .

Abstract

Objective: : To explore illness-related factors in patients with major depressive disorder (MDD) recipients of adjunctive minocycline (200 mg/day) treatment. The analysis included participants experiencing MDD from a 12-week, double blind, placebo-controlled, randomized clinical trial (RCT).

Methods: : This is a sub-analysis of a RCT of all 71 participants who took part in the trial. The impact of illness chronicity (illness duration and number of depressive episodes), systemic illness (endocrine, cardiovascular and obesity), adverse effects and minocycline were evaluated as change from baseline to endpoint (12-week) using ANCOVA.

Results: : There was a consistent but statistically non-significant trend on all outcomes in favour of the use of adjunctive minocycline for participants without systemic illness, less illness chronicity, and fewer adverse effects.

Conclusion: : Understanding the relationship between MDD and illness chronicity, comorbid systemic illness, and adverse effects, can potentially better characterise those individuals who are more likely to respond to adjunctive anti-inflammatory medications.

Keywords: Clinical trial; Depression; Inflammation; Minocycline; Theragnostic; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Gerard Anmella has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck, Lundbeck/ Otsuka, Rovi, Casen Recordati, and Angelini, with no financial or other relationship relevant to the subject of this article.

Chee H. Ng has participated as a consultant for Lundbeck, Grunbiotics, Servier, Janssen-Cilag, and Eli Lilly, received research grant support from Lundbeck, and speaker honoraria from Servier, Lundbeck, Sumitomo, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithKline, Janssen- Cilag, Astra-Zenaca, and Pfizer, unrelated to the submitted work.

Diego Hidalgo-Mazzei has received CME-related honoraria and served as consultant for Abbott, Angelini, Ethypharm Digital Therapy and Janssen-Cilag with no financial or other relationship relevant to the subject of this article.

Iria Grande has received grants and served as consultant, advisor or CME speaker for the following identities: Angelini, Casen Recordati, Ferrer, Janssen Cilag, and Lundbeck, Lundbeck-Otsuka, Luye, SEI Healthcare outside the submitted work.

Isabella Pacchiarotti has received CME-related honoraria, or consulting fees from ADAMED, Janssen-Cilag and Lundbeck (unrelated to the present work).

Andrea Murru has received grants and served as consultant, advisor or CME speaker for the following entities: Angelini, Idorsia, Lundbeck, Pfizer, Takeda, with no financial or other relationship relevant to the subject of this article.

Eduard Vieta has received research support from or served as consultant, adviser or speaker for AB-Biotics, Abbott, Abbvie, Adamed, Angelini, Biogen, Celon, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, GH Research, Glaxo SmithKline, Janssen, Lundbeck, Organon, Otsuka, Rovi, Sage pharmaceuticals, Sanofi- Aventis, Shire, Sunovion, Takeda, and Viatris, out of the submitted work.

Olivia M. Dean has received grant support from the Brain and Behavior Foundation, Marion and EH Flack Trust, Simons Autism Foundation, Australian Rotary Health, Stanley Medical Research Institute, Deakin University, Brazilian Society Mobility Program, Lilly, NHMRC, Australasian Society for Bipolar and Depressive Disorders and Sevier. She has also received in-kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals.

All other authors report no financial or other relationship relevant to the subject of this article.

Figures

Fig. 1
Fig. 1
Differential change from baseline to week 12 in depression-anxiety symptoms, severity, global experience, functioning and quality of life scores according to treatment group (minocycline/placebo) and illness chronicity, systemic illness, and adverse effects. Scale ranges: MADRS (0−60), HAMD (0−52), Q-LES-Q (14−70), LIFE-RIFT (4−20), SOFAS (0−100), PGI (1−7), CGI-S (1−7), CGI-I (1−7). Positive change is indicative of favorable results for every scale in the graph. In all clinical scales, higher scores indicate worse outcomes, except for Q-LES-Q and SOFAS. Therefore the latter were inverted. Changes in PGI and CGI-I were evaluated between week 2 and week 12. BMI, body mass index; CGI-S, Clinical Global Impression-Severity; CGI-I, Clinical Global Impression-Improvement; HAM-A, Anxiety symptoms were assessed with the Hamilton Anxiety Rating Scale; LIFE-RIFT, Range of Impairment Functioning Tool; MADRS, Montgomery–Asberg Rating Scale; PGI, Patient Global Impression; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; SOFAS, Social and Occupational Functioning Assessment Scale.
See this image and copyright information in PMC

References

    1. Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. doi: 10.1038/nrdp.2016.65. - DOI - PubMed
    1. Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–2312. doi: 10.1016/S0140-6736(18)31948-2. - DOI - PubMed
    1. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry. 2004;61:1097–1103. doi: 10.1001/archpsyc.61.11.1097. - DOI - PubMed
    1. Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, et al. Maintenance or discontinuation of antidepressants in primary care. N Engl J Med. 2021;385:1257–1267. doi: 10.1056/NEJMoa2106356. - DOI - PubMed
    1. Boschloo L, Schoevers RA, Beekman AT, Smit JH, van Hemert AM, Penninx BW. The four-year course of major depressive disorder: The role of staging and risk factor determination. Psychother Psychosom. 2014;83:279–288. doi: 10.1159/000362563. - DOI - PubMed